Search the Newsreel

ePlus Inc. (PLUS) Recognized in 2026 MES Midmarket 100 for AI Solutions

ePlus Inc. (PLUS) has been recognized in the 2026 MES Midmarket 100 list by MES Computing for its expertise in assisting mid-sized businesses with AI program planning and deployment. The company's GF Score™ is 83/100, indicating strong potential for long-term returns, but GuruFocus considers …

WCM Investment Management LLC Sells 142,693 Shares of ePlus inc. $PLUS

WCM Investment Management LLC significantly reduced its stake in ePlus inc. by 44.7% in the first quarter, selling 142,693 shares, though it still holds 176,750 shares valued at approximately $13.0 million. This comes as ePlus reported stronger-than-expected quarterly results and increased its dividend, yet …

Plus Therapeutics secures regional coverage for CNSide® assay in Ohio and Kentucky, expanding access to 1.2M people.

Plus Therapeutics' subsidiary, CNSide Diagnostics, has secured a regional agreement with Medical Mutual, extending coverage for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay to 1.2 million people in Ohio and Kentucky. This expansion brings the total national coverage to approximately 127 million people. …

Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases

Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a regional coverage agreement with Medical Mutual, effective July 1, 2026, which expands CNSide® cerebrospinal fluid assay coverage to an additional 1.2 million people in Ohio and Kentucky. This agreement increases the total contracted coverage for …

Precision Trading with Simulations Plus Inc. (SLP) Risk Zones

Simulations Plus Inc. (SLP) is showing a neutral sentiment across all horizons, leading to a wait-and-see approach. AI models suggest several trading strategies, including a short setup with a high risk-reward ratio, targeting a 16.5% downside. The article details entry, target, and stop-loss zones …

Simulations Plus (NASDAQ:SLP) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Simulations Plus (NASDAQ: SLP) saw its share price move above its 200-day moving average, reaching $18.25 despite cautious analyst sentiment and recent downgrades. The company reported strong quarterly earnings, beating expectations with an EPS of $0.30 and revenue of $21.89 million. While a director …

MedPlus Health Q1 net profit falls 22% as margins decline despite 22% revenue growth

Simulations Plus (SLP) to go private in $375M all‑cash sale to Altaris

Simulations Plus (SLP) is set to go private through a $375 million all-cash sale to Altaris, with shareholders receiving $18.50 per share. This represents a 26% premium over the 60-day volume-weighted average price prior to June 15, 2026. The acquisition is expected to close …

Why (PLUS) Price Action Is Critical for Tactical Trading

This article analyzes Eplus Inc. (NASDAQ: PLUS) stock, noting a near-term neutral sentiment amidst mid and long-term strength. It highlights a tactical trading opportunity with an exceptional 35.5:1 risk-reward setup, targeting a 10.2% gain against 0.3% risk. The analysis includes institutional trading strategies for …

Liquidity Mapping Around (NPCT) Price Events

The article provides an AI-generated analysis of Nuveen Core Plus Impact Fund (NPCT), highlighting a neutral sentiment and a mid-channel oscillation pattern. It outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, and details multi-timeframe signal …

Simulations Plus | 144: Notice of proposed sale of securities pursuant to Rule 144

This document is a formal notification regarding the proposed sale of securities by Simulations Plus, carried out under Rule 144 of the Securities Act of 1933. Rule 144 allows for the public resale of restricted and control securities if certain conditions are met. The …

Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold

ePlus (PLUS) Stock Could Be 15% Overvalued As Q1 Beats Land

Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com

Plus Therapeutics (NASDAQ: PSTV) has announced a partnership with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing technology into its CNSide cerebrospinal fluid assay platform. This collaboration aims to enhance the CNSide platform by enabling DNA and RNA profiling across hundreds of biomarkers from …

Cancer guidelines broaden spinal-fluid analysis; Plus plans DNA, RNA

Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing into its CNSide cerebrospinal fluid assay platform. This partnership aims to enable comprehensive DNA and RNA profiling of hundreds of biomarkers from a single CSF specimen, aligning CNSide …

Plus Therapeutics and Genomic Testing Cooperative Partner

Plus Therapeutics and Genomic Testing Cooperative (GTC) have announced a collaboration to integrate GTC's next-generation sequencing technology into Plus Therapeutics' CNSide® cerebrospinal fluid (CSF) assay platform. This partnership aims to provide comprehensive DNA and RNA profiling from a single CSF specimen, aligning with updated …

PLUS THERAPEUTICS (PSTV) Surges 7%: Biotech Momentum Testing Key Resistance - McClellan Summation

SIMULATIONS PLUS ($SLP) Releases Q3 2026 Earnings

Simulations Plus (NASDAQ: SLP) grows Q3 2026 revenue 7% to $21.9M

Is Genusplus Group Ltd (ASX:GNP) Still Worth Watching After Today's Drop?

Computacenter and Plus500 tipped to beat expectations this earnings season

Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting

Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3

Medplus Health Services Share Price Target 2026: Bull Case Rs 1,1295

Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV

Beijing Geekplus Technology Co., Ltd. Class H Actuals & Estimates (HKEX:2590)

PLUS Forecast — Price Target — Prediction for 2027

5N Plus Inc. Actuals & Estimates (TSX:VNP)

Plus Therapeutics gets national health coverage for CNS cancer test

Telecom Plus Launches £40m Share Buyback to Cut Share Capital

Telecom Plus shares slump after growth plan, lower earnings guidance | Financial News

Telecom Plus slashes dividend amid fierce competition

Telecom Plus stock craters 30% after flagging lower profits ahead

Telecom Plus plunges on plan to invest in growing customer network

Companies & Markets Analysis 23/06/2026: Filtronic, Telecom Plus, B.P. Marsh & Partners, Firstcash Holdings (Texas), Ramsdens Holdings, Hercules

Why is Telecom Plus stock plunging today? By Investing.com